Company intelligence / Profile preview

Enquyst Technologies

Lowell, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

IPP technology (patented, resin-free) enables ultra-high purity, scalable continuous downstream purification for biologics, including mAbs and viral vectors, demonstrated with no yield loss and significant cost-of-goods reductions.

Modalities: Monoclonal antibodyBispecific monoclonal antibodyPeptidesRNA therapyPlasmidsViral vectors (AAV, lentiviral)
Industry: Non-Drug Biotech

Partnerships

LonzaMilliporeSigmaUniversity of Massachusetts Lowell (NIIMBL-funded IPP technology development)

Beyond the preview

Go deeper on Enquyst Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enquyst Technologies.

Explore the full profile